Virginia is currently home to 1822 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers
NCT04647240
Recruiting
DL-VSU-201 is a randomized, double-blind, placebo controlled study in subjects with a non-infected venous stasis ulcer (VSU) that has failed to demonstrate improvement after receiving at least 4 weeks of standard, conventional wound therapy to evaluate the efficacy and safety of Dermacyte® Liquid (MTX-001).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Salem Vamc, Salem, Virginia
Conditions: Venous Stasis Ulcer, Venous Leg Ulcer
Register for Updates
Palliative Care Oncology in Patients with Relapsed, Refractory, and High-Risk Leukemias or MDS
NCT04482894
Recruiting
The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Leukemia, Acute, AML, Adult, ALL, Adult, Myelodysplastic Syndromes
Register for Updates
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
NCT06636123
Recruiting
The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Castration-resistant Prostate Cancer
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06627647
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Research Site, Fairfax, Virginia
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
Immune Registry for BK in Kidney Transplant Recipients
NCT06538961
Recruiting
Kidney transplantation (KT) is the best treatment modality available to date for patients with advanced kidney disease and the success of KT is dependent on maintaining a selective intricate balance between the risk of rejection and infections in KT recipients. BK virus is an important clinical infection affecting the post-transplant outcomes in KT recipients. BK nephropathy can affect 8-15% of patients after KT causing acute kidney injury, increased risk of rejection and fibrosis leading to add... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: BK Virus Infection, Kidney Transplant; Complications
Register for Updates
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
02/20/2025
Locations: Research Site 019, Hampton, Virginia
Conditions: COPD
Register for Updates
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302
Recruiting
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Local Institution - 0200, Norfolk, Virginia
Conditions: Lymphoma, Follicular
Register for Updates
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552
Recruiting
The primary purpose of this study is to measure the efficacy and safety of efgartigimod intravenously (IV) compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). Other objectives are to assess long-term efficacy, safety, and tolerability of efgartigimod. Study will consist of: * Screening * Part A: participants will be randomized to receive either efgartigimod IV or placebo * Part B: participants completing p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Generalized Myasthenia Gravis
Register for Updates
Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca
NCT06250751
Recruiting
To refine a remote behavioral exercise training intervention for testing in a larger randomized trial.
Gender:
MALE
Ages:
Between 41 years and 85 years
Trial Updated:
02/20/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Prostate Cancer
Register for Updates
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT06185205
Recruiting
The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.
Gender:
FEMALE
Ages:
Between 45 years and 79 years
Trial Updated:
02/20/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Breast Cancer
Register for Updates
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: NEXT Oncology - Virginia - 1129, Fairfax, Virginia
Conditions: Non Small Cell Lung Cancer
Register for Updates
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843
Recruiting
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to sever... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/20/2025
Locations: Richmond VAMC- Site Number : 8400022, Richmond, Virginia
Conditions: Colitis Ulcerative
Register for Updates